Acute Care Therapeutics for Surgical Settings

Baudax Bio is a pharmaceutical company focused on developing and commercializing innovative products for acute care settings.

About Baudax Bio

We are committed to bringing meaningful therapeutic options to patients, healthcare providers, and payers.  We currently have multiple therapeutic candidates across early, mid and late-stage clinical development, including a FDA approved non-opioid therapy for use in the acute care setting.

About Us

Our Innovative Portfolio & Pipeline

On February 20, 2020, the FDA approved ANJESO (meloxicam) injection, for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.  Our product pipeline contains valuable therapeutic candidates for patients and healthcare providers in acute care settings.

ANJESO (meloxicam) injection

Product Portfolio

Latest News

Baudax Bio Announces $12 Million Offering Priced at a Premium to Market

View Press Release

Baudax Bio Announces $12 Million Offering Priced at a Premium to Market

View Press Release

Baudax Bio Announces Publication of ANJESO® Network Meta-Analysis in the Peer-Reviewed Journal BMC Anesthesiology

View Press Release

Baudax Bio Announces an additional Orange Book listed patent for ANJESO®

View Press Release

Baudax Bio Reports Third Quarter 2020 Financial Results

View Press Release

Baudax Bio to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020

View Press Release

Baudax Bio Provides Commercial and Corporate Update

View Press Release

Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

View Press Release

Baudax Bio to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit

View Press Release

Baudax Bio Awarded Group Purchasing Agreement with Premier Inc. for ANJESO®

View Press Release

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today